Transition report pursuant to Rule 13a-10 or 15d-10

Stock-Based Compensation, Restricted Stock and Stock Options (Details) - Schedule of stock options

v3.22.1
Stock-Based Compensation, Restricted Stock and Stock Options (Details) - Schedule of stock options - Stock Options [Member]
$ / shares in Units, $ in Thousands
 9 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Stock-Based Compensation, Restricted Stock and Stock Options (Details) - Schedule of stock options [Line Items]  
Shares Underlying Options Outstanding | shares 10,928,607 [1]
Weighted Average Exercise Price Outstanding | $ / shares $ 2.73
Weighted Average Remaining Contractual Term (Years) Outstanding 8 years 2 months 12 days
Aggregate Intrinsic Value Outstanding | $ $ 17,524
Shares Underlying Options Granted | shares 1,442,204
Weighted Average Exercise Price Granted | $ / shares $ 3.53
Weighted Average Remaining Contractual Term (Years) Granted 9 years 9 months 18 days
Shares Underlying Options Exercised | shares (419,000)
Weighted Average Exercise Price Exercised | $ / shares $ 0.51
Shares Underlying Options Canceled | shares (816,379)
Weighted Average Exercise Price Canceled | $ / shares $ 3.88
Shares Underlying Options Outstanding | shares 11,135,432
Weighted Average Exercise Price Outstanding | $ / shares $ 2.85
Weighted Average Remaining Contractual Term (Years) Outstanding 7 years 7 months 6 days
Aggregate Intrinsic Value Outstanding | $ $ 13,031
Shares Underlying Options Exercisable | shares 9,850,155
Weighted Average Exercise Price Exercisable | $ / shares $ 2.75
Weighted Average Remaining Contractual Term (Years) Exercisable 7 years 4 months 24 days
Aggregate Intrinsic Value Exercisable | $ $ 12,402
[1] Options outstanding as of March 31, 2021 includes 66,667 options to purchase shares of the Company’s common stock granted on October 16, 2020 and were recorded as an out of period adjustment. The related stock-based compensation of approximately $0.2 million has been expensed during the nine months ended December 31, 2021.